Covid-19 vaccine: Biocon’s US partner Equillium to withdraw Itolizumab trials
US company says it will not initiate Phase-3 clinical trials after reviewing its efficacy
US company says it will not initiate Phase-3 clinical trials after reviewing its efficacy